**Key Points:**

– London-based Isomorphic Labs, a subsidiary of Google AI R&D division DeepMind, has announced partnerships with Eli Lilly and Novartis.
– The goal of these collaborations is to use AI in the discovery of new medications for diseases, pushing the boundaries of medicine.
– The deals are estimated to be worth a combined $3 billion, with upfront payments to Isomorphic amounting to $45 million.

Isomorphic Labs Teams Up with Pharma Big Shots

The AI Revolution in Pharma

Isomorphic Labs, the brainchild of Google AI R&D’s DeepMind, has announced that it’s getting into bed with two pharma bigwigs – Eli Lilly and Novartis. This London-based smarty-pants is bringing AI to the table in a bid to discover new disease-busting drugs.

Partnerships Worth Billions

What’s in it for Isomorphic, you may ask? Well, apart from an exciting scientific partnership, they’re also raking in some serious dough. The contracts estimated to be worth around one big fat $3 billion with an upfront payment of $45 million. Not too shabby, eh?

The Grand AI-Pharma Alliance

DeepMind’s progeny is set on revolutionising the way we find new medications, and with allies like Eli Lilly and Novartis, that doesn’t seem like a pipe dream anymore.

It’s like they say, money makes the world go round… or in this case, AI makes the pharma world go round. With these partnerships, Isomorphic Labs is basically the new kid on the block that everyone wants to be friends with. And I must say, they’re making the best of it. They’re onto something big, something potentially revolutionary, revolutionising how we discover new drugs. And to think… they say AI can’t be creative! Time to sit back and watch as these relationships bloom and hopefully, some pretty amazing, groundbreaking medications pop up. Pass the popcorn, please!

Original article: https://techcrunch.com/2024/01/07/isomorphic-inks-deals-with-eli-lilly-and-novartis-for-drug-discovery/